Home / Health / Revived Drugs: Billions in New Biotech Cures
Revived Drugs: Billions in New Biotech Cures
19 Mar
Summary
- Discontinued drugs offer potential treatments for rare diseases.
- Pfizer's shelved cancer drug became a multi-billion dollar success.
- Thousands of abandoned drug candidates await revival.
Thousands of drug candidates, discontinued for reasons other than safety or efficacy, represent a significant untapped resource for treating rare and neglected diseases. These shelved compounds offer hope for conditions with no current approved therapies.
Pfizer's experimental cancer drug, initially shelved, was repurposed by SpringWorks Therapeutics to treat a rare genetic disorder. This initiative resulted in the FDA and EMA-approved medicine Gomekli, leading to Merck's $3.4 billion acquisition of SpringWorks in spring 2025.
Reviving these assets is not only medically beneficial but also economically advantageous. The success of SpringWorks demonstrates the potential for substantial returns, potentially fueling a new wave of biotech startups by licensing these dormant drug candidates.
Unlocking this potential necessitates a functional market for shelved assets and robust collaboration. Establishing a unified catalog and a matchmaking system to connect drug owners with capable developers and investors is crucial for progress.
